Cloud & SaaS

126 tickers in this theme
Ranks this page's recent reports by score.
CoreWeave, Inc.
CRWV·Technology
B ★★★Hold
Current$92.68
Target$155.60
Return+67.9%
Aug 21, 2026

CoreWeave is the deeply undervalued pure-play architect of the generative AI infrastructure boom, though investors must possess the stomach to endure a highly leveraged balance sheet built upon unrelenting capital expenditures.

Score
80
monday.com Ltd.
MNDY·Technology
A ★★★★Buy
Current$92.12
Target$139.00
Return+50.9%
Aug 20, 2026

monday.com is a highly cash-generative Work OS leader successfully migrating upmarket with its AI product suite, trading at a structurally compressed valuation despite temporary headwinds from a major workforce restructuring and macroeconomic forex friction.

Score
90
Life360, Inc.
LIF·Technology
B ★★★Hold
Current$51.72
Target$61.48
Return+18.9%
Aug 18, 2026

Life360 is an elite, hyper-growth family safety platform expanding rapidly into digital advertising, though investors must carefully navigate near-term dilution risks from convertible debt and heavy insider selling.

Score
79
Octave Intelligence plc
OCTV·Technology
A ★★★★Buy
Current$18.91
Target$32.50
Return+71.9%
Aug 18, 2026

Octave is a highly cash-generative, mission-critical infrastructure software monopoly trading at an irrationally steep discount due to post-spin accounting noise, though investors must tolerate near-term revenue friction as the company aggressively phases out legacy perpetual licenses in favor of cloud subscriptions.

Score
88
Klaviyo, Inc.
KVYO·Technology
B ★★★Hold
Current$18.49
Target$26.31
Return+42.3%
Aug 17, 2026

Klaviyo boasts a highly efficient, Rule of 40-clearing marketing automation platform with deep e-commerce roots, though investors must weigh its impressive cash generation against structural growth deceleration, SMS margin pressures, and heavy insider selling.

Score
78
Amdocs Limited
DOX·Technology
A ★★★★Buy
Current$58.66
Target$81.62
Return+39.1%
Aug 16, 2026

Amdocs is an impenetrable, highly cash-generative tollbooth for global telecom operations trading at a deeply distressed valuation, though investors must accept stagnant top-line growth tied to constrained carrier capital expenditures.

Score
86
NICE Ltd.
NICE·Technology
S ★★★★★Strong Buy
Current$105.25
Target$156.38
Return+48.6%
Aug 15, 2026

NICE is the undisputed, highly profitable tollbooth of enterprise customer orchestration, trading at a deeply distressed valuation due to myopic fears of seat-license cannibalization, offering an immense margin of safety as it flawlessly transitions into the agentic AI consumption era.

Score
100
Nebius Group N.V.
NBIS·Technology
A ★★★★Buy
Current$254.24
Target$353.13
Return+38.9%
Aug 15, 2026

Nebius presents a compelling pure-play AI infrastructure investment, backed by a massive $40 billion backlog and unique software orchestration moats, though extreme capital intensity and execution risks around power delivery require close monitoring.

Score
89
Trimble Inc.
TRMB·Technology
A ★★★★Buy
Current$58.44
Target$83.95
Return+43.7%
Aug 15, 2026

Trimble is rapidly compounding value as an elite, high-margin construction software ecosystem trading at an unwarranted legacy-hardware discount, though investors must navigate the near-term friction of logistics impairments and internal accounting remediations.

Score
89
Bending Spoons S.p.A.
BSP·Technology
C ★★Sell
Current$39.11
Aug 15, 2026

Bending Spoons possesses a highly profitable M&A software roll-up model, yet organic growth is virtually stagnant at 3% and leverage constraints risk throttling the primary driver of its extreme valuation premium.

Score
55
Paylocity Holding Corporation
PCTY·Technology
B ★★★Hold
Current$145.67
Target$159.66
Return+9.6%
Aug 14, 2026

Paylocity is transitioning from a hyper-growth SaaS darling into a highly profitable, deeply undervalued free-cash-flow compounder, though investors must weather near-term headwinds from decelerating mid-market employment growth and shrinking interest income on client funds.

Score
83
Hinge Health, Inc.
HNGE·Healthcare
A ★★★★Buy
Current$86.32
Target$110.00
Return+27.4%
Aug 14, 2026

Hinge Health is the fundamentally dominant, wildly profitable pioneer of the digital musculoskeletal care revolution, poised to capture immense cross-selling upside through its GI expansion, though investors must monitor the intense competitive pricing threats from well-capitalized rivals like Sword Health.

Score
85